RUXOLITINIB INTERMEDIATES

VIDGASTECH provides Ruxolitinib Intermediates with superior purity and stability, supporting the synthesis of JAK inhibitors for myelofibrosis and polycythemia vera treatment.

Additional Content with Keywords:
VIDGASTECH specializes in pharmaceutical-grade Ruxolitinib API intermediates, essential for the production of JAK1/JAK2 inhibitors used in myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD) treatment. With strict GMP compliance, high-purity synthesis, and quality control, our intermediates ensure efficiency in oncology and hematology drug development. As a trusted supplier of Ruxolitinib intermediates, we cater to global pharmaceutical companies developing targeted therapies for hematologic disorders. Contact us for bulk API intermediates and custom synthesis solutions.

1-(1-ethoxyethyl)-4-(4,4,5,5- tetramethyl- 1,3,2-
dioxaborolan-2- yl)-1H-pyrazole
1029716-44-6
1-(1-ethoxyethyl)-4-iodo-1H- pyrazole 575452-22-1
2-isopropoxy-4,4,5,5-tetramethyl- 1,3,2- dioxaborolane 61676-62-8
4-Bromopyrazole 2075-45-8